Background: Exosomes are small vesicles of sizes between 40 and 100 nm. They are actively segregated by numerous different cell types and they can be found in almost all body fluids. Thus, there is an emerging role of exosomes and exosomal deoxyribonucleic acid (exoDNA) in biomedical research, especially in molecular medicine. Exosomes are assembled and segregated actively and carry distinct surface markers for cellular communication. They are loaded with cargo such as DNA, ribonucleic acid (RNA) and proteins. As there are numerous different exosomal purification methods available, it is of essential need to select an appropriate technique to get reliable results. As neuropathology is faced with the challenge that brain tissue is not accessible in an easy fashion, exosomes represent an ideal tool for molecular neuro pathology. Thus, disease-specific molecular alterations will be detectable in a minimally invasive way for early disease diagnosis and surveillance. Summary: The analysis of exoDNA as biomarkers in neuropathology will enable early diagnosis, monitoring and relapse detection of brain tumors and neuropsychiatric disorders. Outlook: It is assumed that the significance of exosomes will increase in the upcoming years. There are powerful approaches in development using exosomes in molecularly targeted therapy to ultimately cure devastating brain diseases.
Introduction
Extracellular vesicles (EVs) are assembled by cells and used for intercellular communication [1] . These vesicles can be distinguished by size and origin. While exosomes are between 40 and 100 nm in size, microvesicles and apoptotic bodies are larger (i.e. approximately 50-1000 nm and 50-5000 nm, respectively) [1] ; however, there is an overlap between the size distribution of these different types of EVs. But EVs can also be distinguished by the way that they are assembled [1, 2] . In contrast to microvesicles that are generated from the cellular plasma membrane [3] and apoptotic bodies that are released from apoptotic cells [2] , exosomes are generated actively by inward budding of endosomal membranes [4] . This way, intracellular multivesicular bodies (MVBs) are generated that fuse with the cellular plasma membrane and release their content, the exosomes, into the intercellular space [5] [6] [7] .
Exosomes are of emerging scientific interest [8] . As it is an essential need for a multicellular organism that different cells and cell populations can communicate with each other, exosomes may be essential in understanding the development and progression of human diseases [2, 4, 9] . Thus, exosome physiology is important in both normal condition and disease [2, 5, 9] .
Interestingly, almost all cells generate exosomes. They represent key factors in bacterial and viral infections, chronic diseases, inflammation, immune response, tumor formation and progression, neurodegeneration, cognitive dysfunctions and psychiatric disorders [1, [10] [11] [12] [13] [14] [15] [16] [17] [18] .
Exosomes can be detected in almost all body fluids, including blood [19, 20] , central spinal fluid (CSF) [21] , urine [22] , saliva [20] , semen [23] and breast milk [20, 24] , making them a major inter-cellular communication system. Interestingly, exosomes are enriched in tumor environment; thus, they are a potential and powerful tool in tumor biology [25] [26] [27] [28] .
As exosomes are present in such a large number of body fluids, they have a large potential as diagnostic markers [29, 30] . They can easily be accessed and they can be used to monitor diseases by repeated analysis without risk for the patients. Furthermore, they have the potential to serve as diagnostic tools for diseases of tissue that cannot be accessed in an easy way [15, 29, 30] . Thus, besides the potential use in tumors, exosomes have a large potential in primary brain diseases such as neurodegeneration and psychiatric disorders [15] [16] [17] [18] .
These features make exosomes an ideal and powerful tool in neuropathology. As neuropathology deals with disorders of the brain, research and diagnosis is faced with the challenge that the primary tissue cannot be accessed in an easy fashion. Till date, brain tumors can be classified only after surgical resection [31] and neurodegenerative diseases can only be diagnosed definitively by the analysis of post-mortem brain specimens [32] [33] [34] [35] [36] [37] [38] [39] . Thus, exosomes represent a potentially powerful new tool for minimally invasive diagnosis of these devastating brain disorders.
Assembly of exosomes
The term exosomes was first introduced in the 1970s by Johnstone [40] and cellular "exfoliations" were first described by Trams in 1981 [9] . Exosomes are assembled in a distinct and highly regulated way [1, 10, 11] (Figure 1) . After endocytosis at the cell membrane, immature endosomes are generated. Invagination of the endosomal membrane occurs in the cytoplasm and cytoplasmic molecules are loaded into the newly generated vesicles. Subsequently, MVBs carry mature exosomes loaded with specific cargo. As far as the MVB membrane fuses with the cell membrane, the exosomes are released into the extracellular space. Exosomes retain the membrane of the cells they originate from and contain additional surface markers to be recognized by the target cells. Thus, analysis of exosomal surface markers potentially enables to determine the tissue that segregated the exosomes into circulation [1, [10] [11] [12] [13] [14] .
In the central exosomal cytosol, different types of proteins and nucleic acids, such as deoxyribonucleic acid (DNA), messenger ribonucleic acid (mRNA), microRNA (miRNA) and long non-coding RNA (lncRNA), are loaded [1, [10] [11] [12] [13] [14] . But the exact composition of the exosomal cargo varies depending on the segregating cells. As exosomes serve for intercellular communication, their generation and release is well controlled by cell type-specific signal transduction pathways. Thus, the generation of exosomes is initiated after cell type-specific stimuli, such as immune response, infection, hypoxia and cellular stress [4, 41, 42] . Ostrowski et al. [43] identified Ras-related in brain (Rab) family members as key regulators in exosome segregation pathways. As prominent Rab family members, Rab27 proteins are involved in tumor formation and progression and their release is triggered in a complex way [43] [44] [45] . This emphasizes exosomes being a key aspect in tumorigenesis.
Surface structure
Exosomes show a distinct surface morphology. Interestingly, not only the content of exosomes is specific for the cells releasing exosomes but also the surface markers of the exosomal membrane are cell type specific [1, [10] [11] [12] [13] [14] . In general, two different types of surface structures can be distinguished: conserved elements and specific elements [1, [10] [11] [12] [13] [14] . While conserved elements are important for the general stability of exosomes, specific elements are important for intercellular communication and signal transduction [1, [10] [11] [12] [13] [14] . As exosomes are segregated by numerous different cells, such as cytotoxic T lymphocytes, B lymphocytes, platelets, dendritic cells and tumor cells, a highly compact surface recognition system is essential for selective intercellular communication [11, 13, 14, 41, 46, 47] . Exosomes have a distinct biogenesis. They originate from the cell membrane (1) . Within the cytoplasm (2), invaginations (3) lead to the formation of multivesicular bodies (MVBs) (4) that are processed by the aid of the endoplasmic reticulum (ER) and lysosomes (5) . Subsequently, their content is actively released from the cells (6) by fusion of MVB with the cell membrane.
Thus, exosomes carry a cell type-specific surface marker enabling a targeted intra-and intercellular communication. The surface markers include not only MVB-related elements, e.g. annexins, GTPases, soluble N-ethylmaleimide-sensitive-factor attachment receptor [48] [49] [50] [51] [52] [53] and Rab proteins [43] [44] [45] [54] [55] [56] [57] [58] , but also membrane-associated surface markers such as CD9, CD63 and CD81 [59, 60] , and in some cases even antigen-presenting molecules (major histocompatibility complex types I and II) [61] . The cell type-specific surface markers are essential for exosome recognition and targeted communication. They can be used for the classification of exosomes.
As the exosomal membrane consists of cell typespecific surface markers, the number of distinct exosomes in the circulation can be quantified precisely [2, [10] [11] [12] [13] [14] . This aspect may especially be interesting in biomarker discovery in the context of detection of diseases, surveillance of therapy and early detection of relapses by quantifying the number of distinct exosomes and by analysis of the content of circulating exosomes [2, [10] [11] [12] [13] [14] .
Acting as cellular "shuttles", exosomes transfer DNA, RNA and proteins between different cells [11, [62] [63] [64] . Currently it is assumed that exosomes carry more than 1600 different mRNAs, 760 different miRNAs and 4500 different proteins [65] [66] [67] . This high diversity of exosomal content reflects the importance of exosomes as a major communication system within the body. To systematically classify exosomes and their cargo, databases such as ExoCarta, Vesiclepedia and EVpedia have been set up [65] [66] [67] [68] [69] [70] [71] . Analysis of exosomal cargo shows that heat shock proteins and CD63 are the most commonly detected exosomal proteins [72] . But there are also numerous proteins that are involved in signal transduction (e.g. WNT and β-catenin) and cytoskeletal stability (e.g. β-actin and tubulins) that are frequently detected in exosomes [73] [74] [75] [76] [77] .
In the target cells, the exosomal content is released into the cytoplasm and intracellular signal transduction cascades are activated. This way, numerous different regulatory pathways are influenced, including immune response and surveillance, inflammation, blood coagulation, tissue repair, neural plasticity, cellular homeostasis and maintenance of stem cells [2, [10] [11] [12] [13] [14] [78] [79] [80] .
Content of exosomes
Recent studies have revealed that exosomes contain varying amounts of DNA, RNA and proteins [1, 2, [10] [11] [12] [13] [14] . Interestingly, there is a significant enrichment of small non-coding RNAs in exosomes, i.e. miRNAs, but there are also numerous other RNAs, e.g. mRNAs, transfer RNAs, lncRNAs, piwi-interacting RNAs, small nucleolar RNAs and small Cajal body specific RNAs [81, 82] . As approximately 50% of genes are regulated by miRNAs, the high concentration of miRNAs in exosomes emphasizes the importance of exosomes in the regulation of cell physiology and inter-cellular communication [82] .
Exosomal proteins are key enzymes in the regulation of signal transduction in target cells: they are released in the target cells and interact in numerous regulatory pathways [1, 2, [10] [11] [12] [13] [14] . Thus, there is the chance to use exosomes as shuttles in gene therapy [1] . First studies revealed that exosomes can be loaded with cargo proteins that can be released into distinct target cells. This is an important novel approach in molecularly targeted gene therapy as distinct cells such as tumor cells can potentially be precisely addressed [1] .
But there is also a significant amount of singlestranded, double-stranded and mitochondrial DNA to be found in exosomes [83] . Thakur et al. [83] revealed that these exosomal DNAs (exoDNA) carry the genetic alterations of the cells releasing the exosomes. They reflect the whole genome of the primary cells and carry the respective mutational status. Thus, studying exoDNA is of emerging importance in tumor research and diagnostics: the mutational status of the tumor cells can potentially be evaluated by analysis of exoDNA [83] . This is potentially feasible by minimally invasive techniques. Thus, there is the chance that tissue of the original tumor can potentially be retrieved in a less risky process. Furthermore, exoDNA seems to be ideal in therapy surveillance and early detection of disease relapse by detecting resistance mutations [83] . As molecular genetic classification of tumors based on mutational profiles and methylation profiling is emerging, there is a great potential for exoDNA in primary tumor classification [31, [83] [84] [85] . However, there is the need for reliable isolation of exosomes to generate reproducible results suitable for diagnostic procedures.
Isolation of exosomes
To analyse exosomes in human diseases, reliable and reproducible isolation methods are needed [86] . The method applied to isolate exosomes is essential and represents a crucial step for downstream analysis. Currently, there are different methods available, each method with distinct advantages and disadvantages.
Till date, there is no unique marker identified for exosomes. Thus, most isolation protocols, such as gradient centrifugation, sediment centrifugation, ultracentrifugation, and size exclusion chromatography are based on size and buoyant density. Subsequently, these approaches cannot distinguish between exosomes, apoptotic bodies and small microvesicles with a size range between 50 and 200 nm, not being able to retrieve a pure exosomal population. Consequently, most analysis are performed on EVs rather than on pure exosomal populations. To solve this challenge, there is a need to identify distinct surface markers that would enable to identify exosomes and to distinguish them from other EVs.
Promising novel approaches in exosome isolation and characterization are the use of magnetic bead cell sorting (MACS) to isolate exosomes as well as flow cytometry for subsequent characterization of MACS-purified vesicles [87] [88] [89] . MACS is a powerful approach to separate different EV populations using surface markers. Although it is still very challenging to separate different EV populations by MACS and to distinguish them by flow cytometry, it is likely that with the discovery of unique surface markers characterizing distinct EV populations, such as exosomes, apoptotic bodies and other microvesicles, these techniques will be the gold standard in exosome research in the near future. Till date, the most commonly used isolation methods are still based on centrifugation. Lane et al. [86] performed a comprehensive analysis of different exosome purification methods.
Gradient centrifugation purification is a method that requires only minimal laboratory equipment and thus can easily be applied in a broad range of laboratories. Exosomes are separated by different buffer gradients and a high number of exosomes are retrieved. However, there is also a large variation in particle size. This may be due to lacking specificity during the isolation protocol and may be problematic in diagnostic procedures [86] .
Sediment centrifugation is another protocol that can easily be applied. This technique requires only minimal equipment. Exosomes are isolated using different sedimentation protocols using benchtop centrifuges. The number of exosomes retrieved by this method significantly varies depending on the applied protocol, but in general numerous particles are recovered. However, there is a quite large distribution in particle size, i.e. it is not feasible to isolate vesicles of distinct sizes [86] .
Ultracentrifugation is one of the most commonly used methods for exosome isolation. Using speeds of approximately 100,000 g exosomes are sedimented from solutions. The recovery of exosomes is relatively low, but this method has a huge advantage compared with the two above stated ones: The exosomal fraction is very pure and the size distribution of particles is relatively small. Results generated in downstream applications are based on relatively homogeneous particles, thus being more reliable compared with the first two methods [86] .
In summary, the applied isolation method is a very crucial step for efficacy of exosome isolation. The results of isolation methods significantly vary in the quantity and quality of exosomes. Only by selecting the appropriate method, reliable results can be generated in downstream analysis, e.g. for applying exosome analysis as minimally invasive technique in molecular diagnostics of cancer by detecting cancer-specific genomic alterations [86] . As standardized protocols for exosomal isolation are still lacking in biomedical research and diagnostics, isolation, enumeration and characterization of EVs such as exosomes are still challenging and reliable diagnostics on exosomes is not yet a reality. Thus, there is a need for multi-center studies and quality assessments enabling to generate conscious results being the basis for reliable exosome-based research and the use of exosomes as biomarkers in medical diagnostics.
Analysis and characterization of exosomes and EV
Currently, there are numerous different techniques applied to characterize exosomes and EVs. Thereby, nanoparticle tracking analysis, Western blot, transmission electron microscopy (TEM) and flow cytometry are routinely used [90] [91] [92] . As stated earlier, promising novel approaches in exosome characterization are the use of MACS and flow cytometry [87] [88] [89] . Using distinct surface markers these powerful approaches will emerge to characterize different EV populations. Fluorescence-activated cell sorting is a well-established technique that will be refined to analyze exosomes and EVs. This technique uses specific antibodies to label surface markers. By fluorescence labeling, particles can be detected using an optical laser device. By charging the target particles, they are subsequently analyzed. However, this method has high requirements: flow cytometers are very expensive, they have high running costs and the laboratory must be equipped adequately to run a flow cytometer. With further advances in flow cytometric technology featuring increased resolution images and fluorescent sensitivity, it will possibly enable to use flow cytometry to analyze and characterize EV directly in the near future. This would allow a more differentiated characterization of EV and would enable the detection of subgroups based on differing protein expression detected by specific antibodies [93] [94] [95] .
Molecular classification of brain tumors
Brain tumors are classified worldwide according to the criteria stated by the World Health Organization (WHO) [31] . With the revised 4 th edition of the WHO classification of tumors of the central nervous system published in 2016, molecular pathological features were included as essential aspects in the classification of tumors [31] . Thus, an integrated diagnosis implying both histology and genetics is recommended in brain tumor diagnostics [31] . Thereby, molecular genetic aspects imply biological, therapeutic and prognostic relevance [31, 96, 97] .
Diffuse and anaplastic glioma can be classified by analysis of distinct molecular features (Figure 2 ) [31] . Two main characteristics of glioma classification are isocitrate dehydrogenase (IDH) 1/2 mutation status and the loss of chromosomal material on the short arm of chromosome 1 (1p) and on the long arm of chromosome 19 (19q) [31] . While diffuse and anaplastic astrocytoma as well as secondary glioblastoma typically show IDH mutations, most commonly at position 132 of the IDH1 gene (p.R132H), primary (de novo) glioblastoma are characterized by the absence of IDH1/2 mutations. Furthermore, these tumors do not show loss of chromosomal material on 1p and 19q [31] . In contrast, oligodendroglioma and anaplastic oligodendroglioma are molecularly characterized by IDH mutations and loss of chromosomal material on 1p and 19q (LOH1p/19q) [31] . Mutations within the alpha thalassemia/mental retardation syndrome X-linked (ATRX) gene are inversely correlated with LOH1p/19q, i.e. while oligodendroglioma show a loss of chromosomal material on 1p and 19q, astrocytoma show mutations within ATRX [31] .
Mutations in histone H3 variants are a typical feature of pediatric and midline high grade glioma [31, 84, 85] . Thus, the analysis of histone H3 family member 3A (H3F3A), histone cluster 1 H3 family member B (HIST1H3B) and histone cluster 1 H3 family member C (HIST1H3C) status is essential to identify these highly malignant childhood and midline gliomas showing a very poor outcome [31, 84, 85] .
In terms of anti-tumor therapy, the determination of the O 6 -alkylguanine DNA alkyltransferase (MGMT) promoter methylation status is essential [31, 98, 99] . Numerous studies have shown that gliomas with a methylated MGMT promoter have a significantly better response to chemotherapy using alcylating agents such as temozolomide (Temodal) and overall survival of patients with a methylated MGMT promoter is significantly longer compared with an unmethylated MGMT promoter [31, .
While diffuse and anaplastic gliomas show IDH1/2 mutations, low grade pilocytic astrocytoma are characterized by B-Raf protooncogene (BRAF) alterations [31] . The most common mutation of BRAF can be found at position 600 (p.V600E), but there are also fusions of BRAF with KIAA1549 that can be detected in distinct low grade gliomas [31] .
Medulloblastomas are highly malignant, embryonal tumors of the cerebellum that occur most frequently in children and young adults [31] . It is assumed that medulloblastomas derive from immature neuronal progenitor cells of the cerebellum [31] . These tumors can be classified histologically; however, there is no good correlation between histological subtype and outcome [31] . Recent findings in molecular pathology revealed that molecular classification is a much better approach with high reliability and a good predictor of patient outcome ( Figure 3 ) [31, 119, 120] . These tumors show distinct alterations in signal pathways, gene expression and methylation profile [31] . Accordingly, medulloblastomas can be classified into four distinct molecular subgroups: WNT-activated, sonic hedgehog (SHH)-activated (with or without TP53 mutation) and group 3 and group 4 tumors. Interestingly, there is a very good correlation between the molecular stratification and the outcome: medulloblastomas with altered WNT signaling pathway show a very good outcome. In the case of medulloblastomas with an altered SHH pathway, the outcome depends on the TP53 mutation status. While SHHaltered medulloblastomas with TP53 wildtype show an intermediate to variable outcome, SHH medulloblastomas with TP53 mutation show a poor outcome. Medulloblastomas without alterations of the WNT and SHH signaling pathway (non-WNT/non-SHH tumors, i.e. groups 3 and 4 according to expression and methylation profiling) show a poor outcome [31] . Alterations of WNT and SHH pathways can be allocated to mutations in distinct genes: while WNT-altered medulloblastoma typically show mutations of catenin beta 1 (CTNNB1), SHH-altered tumors typically show mutations of smoothened (SMO) or patched homolog 1 (PTCH1) [31] . In the case of non-WNT/non-SHH medulloblastomas, no distinct mutations have been identified till date [31] . Thus, these tumors are classified as non-WMT/non-SHH medulloblastomas according to the current WHO classification [31] . In summary, the genetic analysis of CTNNB1, SMO and PTCH1 can be applied for an advanced molecular classification of medulloblastomas [31] .
Meningiomas are benign tumors of the meninges. They show a slow growth and do not infiltrate into the surrounding structures [31] . However, some meningiomas show malignant transformation with significantly decreased survival times. Recent studies have shown that these more aggressive meningiomas frequently show mutations within the telomerase reverse transcriptase (TERT) promoter sequence [31, 121, 122] . Thus, TERT analysis can be used for early identification of meningiomas with increased risk of malignant transformation [31, 121, 122] .
Application of exoDNA analysis in neuropathology
In molecular neuropathology, there are numerous applications potentially benefiting from exosome analysis ( Table 1) . As described earlier, the classification of brain tumors integrates numerous molecular findings for a better tumor stratification [31] . Mutations in distinct genes are characteristic for distinct tumor entities. Consequently, the detection of these mutations is also essential for appropriate treatment of patients.
As there is first evidence that DNA stored in exosomes (exoDNA) shows at least in parts the same genomic alterations as the tumor cells having released the exosomes, it may be feasible to detect tumor mutations by exosome analysis [83] . García-Romero et al. [123] showed that glioma-derived EVs such as exosomes and apoptotic bodies can be detected in peripheral blood and that they carry the relevant glioma-specific DNA mutations, such as AKT3, CDK4, CDKN2A, EGFR, ERBB2, IDH1/2, MDM2, PTEN and TP53. This study showed that exoDNA reflects crucial DNA alterations of the exosome releasing tumors.
However, there is the question if indeed the complete tumor genome is reflected by exoDNA or if only parts of the tumor genome are reflected by exoDNA. Furthermore, there is a significant intratumoral heterogeneity in brain tumors [124] . This is another challenging aspect as it is not yet clarified if analysis of exoDNA is applicable to identify genomic patterns of distinct glioma cell subpopulations that may drive tumor progression. Recent studies on the potential use of exosomes imply an important role of exoDNA in irradiation of gliomas [125] , immune suppression of gliomas [126] , anti-tumor immune activity [90] and hypoxia [127] showing numerous potential novel approaches in using EV in brain tumor research and diagnostics.
As gliomas can be classified by means of genome, epigenome and transcriptome analysis, there are attempts to perform molecular brain tumor diagnosis using exosome analysis. Applying gene panel sequencing, numerous typical genetic marks can be detected in parallel [128] . This way, a molecular assignment of the genetic profile retrieved in tumor-derived exosomes may potentially enable a reliable tumor classification. A further approach in molecular neuropathology is to classify brain disorders by epigenomic profiling [31, 84, 85] . Interestingly, brain tumors can be classified in a reliable manner according to their methylation profile [31, 84, 85] . This approach is even more precise as mutational analysis in terms of tumor biology and patient survival [31, 84, 85] . However, more studies are needed to clarify if exosome analysis and sequencing of exoDNA by next-generation sequencing (NGS) gene panels is a fashionable and reliable way in integrated neuropathological diagnostics. There is still a long way to go till these interesting approaches can be applied in routine diagnostics.
Another interesting aspect is the analysis of gliomaderived RNA stored in exosomes. Skog et al. [129] demonstrated that mutations of the epidermal growth factor receptor (EGFR) mRNA are preserved in exosomes released from glioblastoma cells both in vitro and in vivo. The analysis of exosomes would facilitate diagnosis in brain tumors, neurodegeneration (e.g. Alzheimer's disease, Parkinson's disease, Creutzfeldt-Jacob disease) and psychiatric diseases (e.g. schizophrenia) enabling early detection and minimally invasive surveillance of disease progression by blood and CSF analysis.
This way, clinically relevant EGFR variants (e.g. EGFRvIII) may be detectable using exosome analysis. In the context of glioma diagnostics, IDH mutations are of special interest as they predominantly occur in diffuse and anaplastic glioma as well as in secondary glioblastoma. By analysis of exosomes, these characteristic IDH mutations may be detectable, both at the DNA and at the RNA levels [123, 130] . The MGMT promoter methylation is of crucial importance for therapy planning in glioma patients. Studies analyzing the MGMT promoter methylation and mRNA levels showed that there is a good correlation between methylation and transcription level [131] . Thus, the question rises if differences in the mRNA levels of glioma patients can also be detected by means of exosome analysis. And indeed, Shao et al. [132] demonstrated that altered MGMT mRNA levels can be detected in glioma-derived exosomes and showed that there is a correlation between exosomal MGMT RNA content and therapeutic resistance to temozolomide. Besides mRNAs, another important approach in tumor research and diagnosis is the analysis of non-coding RNA, such as miRNA. As aberrant miRNA expression profiles have been linked to gliomagenesis [130] , the analysis of exosome-derived miRNA profiles will offer another powerful tool in the near future in the fight against brain tumors. But exosomes not only offer novel diagnostic opportunities but also open novel therapeutic fields. One prominent example is the delivery of proteins by modified exosomes to tumor cells [91] . This novel approach will facilitate to deliver therapeutic proteins and agents directly to tumor cells by neglecting healthy cells and subsequently reducing therapeutic by-effects in cancer patients.
Exosome analysis is also of emerging importance in therapy surveillance. As brain tumors, such as gliomas, are diffusely infiltrating tumors, they cannot be resected in toto [31] . Continuous surveillance of glioma patients is essential for the early detection of relapses. Till date, relapses can only be detected by radiological means. Magnet resonance imaging and positron emission tomography scans are performed regularly in glioma patients to detect morphologically visible recurrences of the tumors [31] . Exosomes and the analysis of exosomal proteins will offer novel approaches in therapy surveillance enabling to easily detect glioma recurrence and progression [2, 92] . First clinical phase I trials investigating the applicability of exosomes in patients with malignant glioma have been completed [2] ; however, these techniques are still faced with the problem of lacking sensitivity e.g. in small tumors.
As a striking advantage of exosomes, they can be retrieved easily in a minimally invasive way, e.g. by taking patients' blood or CSF [13] . Thus, exosomes and exoDNA analysis are ideal for disease monitoring. Treatment failure and tumor relapse can potentially be detected early.
However, a crucial aspect in EV research is the specificity and reliability of exosomes as biomarkers. The human blood contains numerous different EVs segregated by a huge number of different cells, most of which do not represent glioma cells. Thus, there is the need to define means that would enable to identify the origins of exosomes in order to enhance the specificity of exosome analysis by isolating only distinct, tumor-derived exosomes to use these EVs as disease markers. Solving this problem will be the crucial step in establishing exosome analysis in routine diagnostics.
But there are also numerous potential applications of exosome diagnostics in other neurological disorders. Currently, the definite diagnosis of neurodegenerative diseases is performed on post-mortem analysis of brain tissue. Alzheimer's disease (AD) is classified by evaluating the amount of amyloid β and τ deposits [32, 34, 36] , Parkinson's disease (PD) is classified by evaluating the amount of α-synuclein [38, 133, 134] and Creutzfeldt-Jacob disease (CJD) is diagnosed by detecting deposits of prion protein in different brain regions using post-mortem tissue [39] . In terms of psychiatric diseases, such as schizophrenia, there is currently only the possibility of a clinical diagnosis but there are no morphological criteria available to date [135] . However, there are first results on molecular alterations occurring during schizophrenia [136] [137] [138] . Thus, there is the need for a refined diagnosis. Current studies on neurodegenerative and psychiatric diseases reveal that there are distinct alterations of the epigenome in the primarily affected brain cells [139] [140] [141] . However, these alterations are not represented in peripheral cells, such as peripheral blood cells. As exoDNA carries genomic patterns of cells releasing exosomes, analysis of exoDNA would be the first feasible approach of definite vital diagnosis of neurodegenerative and psychiatric diseases. Early biomarkers detected in affected brain cells can potentially be used for neuropathological diagnosis even before first clinical symptoms can be recognized [1, 142] .
Despite considerable progress of EV and exosomes as biomarkers, their use in clinical settings is still very challenging and thus limited. First evidence shows that exoDNA represents the genomic signature of the primary cell releasing these vesicles, but it is still to clarify if the complete primary tumor is represented by exosomes retrieved in patients' blood or CSF. As gliomas are very heterogeneous tumors [124] with different clones evolving during tumorigenesis, the question rises if tumor heterogeneity is reflected by different exosomes.
In summary, exosomes and analysis of exoDNA will be of increasing importance in molecular neuropathology. Especially diagnosis, therapy surveillance and early detection of disease relapses will significantly profit from exosome analysis, both in the setting of brain tumors and in neurodegeneration, such as AD and PD, as well as in psychiatric disorders. Thus, exosome analysis represent a major diagnostic aspect of future neuropathology.
Summary
The use of exosomes reveals numerous potential new approaches in molecular neuropathology. Molecularly targeted therapies using exosomes as vehicles will potentially enable to affect only distinct target cells while "healthy" cells will be unaffected. The adverse effects of current systemic therapies will be significantly reduced, and the effectiveness of therapy will be increased. Using exosome shuttles with genome editing techniques opens the door to correct genomic alterations that cause diseases. There are countless possibilities for exosome techniques both in cancer and neuro-psychiatric diseases. Thus, exosomes represent a key aspect in future molecular medicine [83, 142] .
Outlook
In recent years, there has been an emergence of exosomes in biomedical research [1, 2, [10] [11] [12] [13] . As exosomes are actively released by distinct cells for intercellular communication, they represent key factors in inflammation, immune response and diseases [1, 2, [10] [11] [12] [13] . Current studies analyze the applicability of exosome analysis in terms of molecular biomarkers in disease detection and surveillance [8, 143, 144] .
But there is also the chance to use exosomes in molecularly targeted therapeutic approaches (Figure 4) [1, 13, 142] . As exosomes carry distinct surface markers, they can be detected by distinct target cells for cell to cell communication. Furthermore, exosomes can pass the blood-brain barrier (BBB) [145] [146] [147] . Thus, they can potentially be used to deliver small molecules, enzymes, RNA and DNA to brain tissue. Recent developments use exosomes applying RNA interference to inhibit distinct regulatory pathways by introducing small interfering RNAs (siRNAs) or small helical RNA (shRNAs) into cells [1] . This approach opens the possibility to transport RNA to defined cells, e.g. cancer cells. Subsequently, only the tumor cells will be addressed by the therapy, the surrounding physiological tissue will be unaffected. In contrast to current cancer therapy, e.g. irradiation and chemotherapy, this novel approach will Exosomes can potentially be loaded with different cargo such as small molecules, enzymes, siRNA and shRNA, and they can potentaily be used for genomic engineering (e.g. CRISPR/cas9, dcas9). As exosomes can pass the blood-brain barrier (BBB), they can potentially be used to deliver cargo to target cells within the brain with high concentrations. Assembly of exosomes with surface markers and receptors recognized by tumor cells will enable molecularly targeted therapy with high sensitivity and specificity.
potentially be much more efficient as tumor cells can be targeted with high amounts of therapeutic agents and the adverse effects for the patient will be very small [1, 142, 148] . Only within the tumor cells, the exosomal cargo will be released. Possible approaches are to inhibit distinct pathways essential for tumor growth, to correct genomic alterations within the tumor genome by genomic engineering, e.g. using Clustered Regularly Interspaced Short Palindromic Repeats/CRISPR-associated (CRISPR/cas9) or to modulate the tumor epigenome, e.g. using dead cas9 (dcas9) by using exosomes as carrier vehicles [1, 148, 149] . There is also the chance to use exosomes to activate or modulate the immune system so that the tumor cells are recognized by immune cells [150] . Besides the applicability in cancer, exosomes can potentially also be used in other diseases such as neurodegeneration and psychiatric disorders.
In summary, exosomes will revolute both diagnostics and therapy in medicine. They will open new ways for molecularly targeted therapy. Thus, exosome research will help to cure countless patients suffering from devastating diseases.
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